Search
ISSN:
eISSN:
Disciplines
(Field of Science):
- biomedical engineering (Engineering and Technology)
- materials engineering (Engineering and Technology)
- medical biology (Medical and Health Sciences )
- pharmacology and pharmacy (Medical and Health Sciences )
- agriculture and horticulture (Agricultural sciences)
- biotechnology (Natural sciences)
- chemical sciences (Natural sciences)
(Field of Science)
Ministry points: Help
| Year | Points | List |
|---|---|---|
| Year 2024 | 140 | Ministry scored journals list 2024 |
| Year | Points | List |
|---|---|---|
| 2024 | 140 | Ministry scored journals list 2024 |
| 2023 | 140 | Ministry Scored Journals List |
| 2022 | 140 | Ministry Scored Journals List 2019-2022 |
| 2021 | 140 | Ministry Scored Journals List 2019-2022 |
| 2020 | 140 | Ministry Scored Journals List 2019-2022 |
| 2019 | 140 | Ministry Scored Journals List 2019-2022 |
Model:
Points CiteScore:
| Year | Points |
|---|---|
| Year 2022 | 16.7 |
| Year | Points |
|---|---|
| 2022 | 16.7 |
| 2021 | 13.1 |
| 2020 | 8.3 |
| 2019 | 8.2 |
| 2018 | 5.5 |
| 2017 | 4.3 |
| 2016 | 2.9 |
| 2015 | 2.7 |
| 2014 | 1.9 |
Impact Factor:
Sherpa Romeo:
Papers published in journal
Filters
total: 2
Catalog Journals
Year 2021
-
Novel insights into conjugation of antitumor-active unsymmetrical bisacridine C-2028 with glutathione: characteristics of non-enzymatic and glutathione S-transferase-mediated reactions
PublicationUnsymmetrical bisacridines (UAs) are a novel potent class of antitumor-active therapeutics. A significant route of phase II drug metabolism is conjugation with glutathione (GSH), which can be non-enzymatic and/or catalyzed by GSH-dependent enzymes. The aim of this work was to investigate the GSH-mediated metabolic pathway of a representative UA, C 2028. GSH supplemented incubations of C-2028 with rat, but not with human, liver...
Year 2020
-
Electrochemical and in silico approaches for liver metabolic oxidation of antitumor-active triazoloacridinone C -1305
Publication5-Dimethylaminopropylamino-8-hydroxytriazoloacridinone (C-1305) is a promising antitumor compound developed in our laboratory. A better understanding of its metabolic transformations is still needed to explain the multidirectional mechanism of pharmacological action of triazoloacridinone derivatives at all. Thus, the aim of the current work was to predict oxidative pathways of C-1305 that would reflect its phase I metabolism. The...
seen 409 times